• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Betapace, the brand name for sotalol, is a class III antiarrhythmic agent that also possesses non-selective beta-blocker properties. It is primarily used for the treatment of life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm in patients with atrial fibrillation or atrial flutter. Developed in the 1960s and approved by the FDA in 1992, 300mg sotalol occupies a unique niche among antiarrhythmics due to its dual mechanism of action. This report provides a comprehensive overview of Betapace, including its pharmacology, clinical indications, dosing, efficacy, adverse effects, interactions, and monitoring requirements.

Pharmacology and Mechanism of Action

Sotalol is a racemic mixture of two enantiomers, each contributing to its activity. The D-isomer is responsible for class III antiarrhythmic effects by blocking potassium channels (specifically the rapid component of the delayed rectifier potassium current, IKr), prolonging the cardiac action potential duration and refractory period. The L-isomer provides non-selective beta-adrenoceptor blockade (class II effect), reducing heart rate, myocardial contractility, and atrioventricular conduction. This dual action results in both antiarrhythmic and rate-control effects. However, the beta-blocking potency of sotalol is less than that of propranolol, and its class III effect is most pronounced at higher doses.

Sotalol is a hydrophilic compound with low lipid solubility, resulting in minimal central nervous system penetration compared to lipophilic beta-blockers. It has a high oral bioavailability (90–100%) and a long elimination half-life of about 12 hours, allowing twice-daily dosing. It is eliminated primarily unchanged by the kidneys; thus dose adjustments are required in patients with renal impairment.

Clinical Indications

Betapace is indicated for the treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia. It is also used for the maintenance of sinus rhythm in patients with symptomatic atrial fibrillation or atrial flutter, though it is not a first-line agent for rate control. In many guidelines, sotalol is considered an alternative to amiodarone or flecainide in patients without structural heart disease or coronary artery disease. Its use is contraindicated in patients with a prolonged QT interval, severe renal impairment (creatinine clearance <40 mL/min), or certain bronchospastic conditions.

Dosing and Administration

The typical starting dose for Betapace is 80 mg twice daily, which may be increased to 160 mg twice daily based on response and tolerance. For ventricular arrhythmias, doses up to 320 mg per day may be used. Due to the risk of proarrhythmia (particularly torsade de pointes), therapy is typically initiated in a hospital setting with continuous ECG monitoring. The dose must be carefully titrated, with at least three days between increments to allow steady-state drug levels. In patients with renal impairment, the dosing interval is extended (e.g., once daily for creatinine clearance 30–60 mL/min). Sotalol should be taken on an empty stomach to avoid decreased absorption.

Efficacy

Sotalol has been shown to be effective in suppressing ventricular arrhythmias and reducing the incidence of spontaneous ventricular tachycardia. In atrial fibrillation, it is comparable to other antiarrhythmics like amiodarone in maintaining sinus rhythm at one year, although its tolerability may be lower. The D-isomer form (sotalol) has been studied in clinical trials such as the SWORD study, which unfortunately showed increased mortality in patients with left ventricular dysfunction when using high-dose D-sotalol. As a result, sotalol is generally avoided in patients with heart failure or significant structural heart disease. The beta-blocking effect of racemic sotalol may mitigate some risks, but caution remains.

Adverse Effects

The most concerning adverse effect of Betapace is proarrhythmia, particularly torsade de pointes due to the class III effect prolonging the QT interval. The incidence is dose-related and higher in patients with hypokalemia, hypomagnesemia, bradycardia, or renal impairment. Beta-blocker side effects include bradycardia, hypotension, fatigue, dizziness, and bronchospasm. Other common effects include gastrointestinal disturbances, headache, and sleep disturbances (though less than with lipophilic beta-blockers). Rare but serious side effects include heart failure exacerbation, second-degree heart block, and ventricular fibrillation. Monitoring of electrolytes, renal function, and QT interval is mandatory.

Drug Interactions

Sotalol should not be used with other drugs that prolong the QT interval (e.g., certain antipsychotics, macrolides, fluoroquinolones, or class I/III antiarrhythmics). Concurrent use with other beta-blockers or calcium channel blockers (verapamil, diltiazem) may cause additive bradycardia or heart block. Diuretics that deplete potassium or magnesium increase the risk of proarrhythmia. Antiarrhythmic drugs like amiodarone should be used with extreme caution and only after a washout period. Digitalis may enhance the risk of bradyarrhythmias.

Monitoring and Patient Counseling

Before initiating Betapace, patients should have a baseline ECG (with QT interval measurement), serum electrolytes (potassium, magnesium), and renal function tests. During therapy, periodic ECGs and electrolyte checks are recommended. Patients should be advised to report symptoms such as palpitations, syncope, or severe dizziness. They should avoid sudden discontinuation due to the risk of rebound tachycardia or angina. Caution is needed in pregnancy and lactation; it is classified as FDA pregnancy category B (no adequate studies in humans, but animal studies show risk).

Conclusion

Betapace (sotalol) remains a valuable agent in the management of life-threatening ventricular arrhythmias and certain supraventricular arrhythmias. Its dual mechanism provides both antiarrhythmic and rate-slowing effects, but careful patient selection and monitoring are essential to minimize the risk of proarrhythmia. Due to its renal elimination, dose adjustments are critical. While newer antiarrhythmic drugs have been developed, sotalol’s long history and established efficacy ensure its continued use in carefully chosen patients under close supervision.